openPR Logo
Press release

Dual Chamber Injection Device Market to Reach $5.3 Billion by 2024

12-01-2017 09:31 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The need to reconstitute lyophilized drugs at the point of administration and the potential safety and compliance issues this represents for patients have led to increasing interest in injection devices that can eliminate the number of steps required to convert the drug powder to liquid form and make it available for injection. Dual chamber syringes and injectors – devices that allow reconstitution to take place within the device immediately prior to injection - are the most elegant engineering solution to this need. As more drug developers move toward these devices, the value of dual chamber-delivered drug therapeutics will reach $5.3 billion annually by 2024.

The inherent instability of important drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are administered. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the ‘Cold Chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to administration.

While the majority of dual chamber injection devices in currently marketed drug-device products are custom implementations a few companies, most notably Ypsomed and Vetter, offer standard dual chamber device platform solutions for drug developers. This strategy typically reduces development costs and time-to-market at the possible expense of creating a somewhat less-than-unique product look and feel from a branding perspective. Suppliers of dual chamber drug cartridges, which are designed to fit within a pen injector body, operate either on a traditional OEM outsource contract basis, or in the case of vertically integrated device suppliers, as turnkey cartridge-and-device solution suppliers.

In terms of market penetration, dual chamber injection devices have a significant presence in seven major therapeutic segments. We expect this number to grow as the influence of environmentally sensitive drugs on therapeutic patient care increases.

These findings are contained in a new and comprehensive report researched and written by Greystone Research Associates. Dual Chamber Syringes & Injectors to 2024: Devices, Therapeutics, Markets, Players and Forecasts includes detailed analysis of dual chamber devices, an analysis of dual chamber device markets, assessments of dual chamber device/drug products, and profiles of market participants.

More information is available at www.greystoneassociates.org .

Source: Greystone Research Associates

About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
mksmith@greystoneassociates.org
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dual Chamber Injection Device Market to Reach $5.3 Billion by 2024 here

News-ID: 840278 • Views: 175

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for Amherst

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Evolution in Markets for Radiation Curable Coatings Creating Risks and Opportuni …
(Amherst, NH) – Recent advances in materials and equipment are creating new demand for radiation curable coatings in a number of industrial applications. This new demand is occurring as several technology advances are being brought into the marketplace. By removing some of the key limitations of radcure coatings, these advances are enabling radcure coatings to meet unique application requirements, opening up a number of new opportunities. Technical advances that are having
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,
Esensors Adds New Websensor Features
July 22, 2008 – Amherst, NY – EM01B Websensor is an environmental sensor that provides accurate measurement of temperature, relative humidity and light over a network. This month, Esensors adds some new features to EM01B Websensor. The free Websensor Data Logger now enables users to easily export the data to other software tools for analysis. This allows the flexibility to generate custom data views and make data collection more